Background Losartan is a selective angiotensin AT1 receptor antagonist currently employed in the management of essential hypertension. This compound is in common use in populations with renal failure and end-stage renal disease (ESRD). Objective To investigate the pharmacokinetics and pharmacodynamics of losartan in patients with ESRD in order to establish administration guidelines. Methods
After adjustment, there were significant relative risk reductions for losartan compared with placebo for ESRD and for ESRD or death regardless
The pharmacokinetics of losartan and its active metabolite are linear with oral losartan doses up to 200 For the primary endpoint and ESRD, the effects of
losartan on renal and cardiovascular outcomes in patients with end-stage renal disease (ESRD), or death. The secondary outcome was
While even mild anemia may be a risk factor for progression of CKD and for poor outcomes, these analyses suggest that the beneficial effects of treatment with losartan in this patient population on ESRD, ESRD or death, and proteinuria persisted in the presence of hemoglobin decrease.
by WKOK SENG 2024 Cited by 20Total cost, converted to US dollars, was the sum of ESRD and losartan costs. Results: Losartan plus CT reduced the number of days with ESRD by
by E Ripley 2024 Cited by 55left ventricular hypertrophy by losartan versus atenolol: the losartan losartan on the lifetime incidence of ESRD and costs in mexico. Rev. Invest
by E Ripley 2024 Cited by 55left ventricular hypertrophy by losartan versus atenolol: the losartan losartan on the lifetime incidence of ESRD and costs in mexico. Rev. Invest
Losartan Unknown Status Phase 4 Trials for Peritoneal dialysis therapy / End Stage Renal Disease (ESRD) Prevention Effect of Add-on Spironolactone to Losartan
Comments